Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 437 participants.

Also called NCT02582242

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 437 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02582242
Other papers using this trial's data
  • Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs Diabetes research and clinical practice, 2019-04 DOI, PubMed 30872064

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Algeria, China, Hong Kong SAR China, India, Taiwan, Türkiye, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02582242. Randomized; no masking; primary purpose treatment. Start 2015-10-19 (actual); primary completion 2017-03-18 (actual). Results posted on 2018-05-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
Condition
Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
biphasic insulin aspart 30
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02582242
Content hash
76adbeab8c83bead78fdc47716afef1f5b70743a4e079cdca2a50ee0c3f2dde2